Advanced Prostate Cancer VL

Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard

Details
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...

CAR T and Cellular-Based Therapies - Vivek Narayan

Details
Vivek Narayan joins Alicia Morgans at ASCO 2022 to discuss his work with CAR T-cell therapies and prostate cancer, the first-in-human study. Using a low-dose escalation approach, Dr. Narayan and his team designed the study safety as the primary objective to evaluate the feasibility of manufacturing and delivering the CAR T-cells. He describes how findings showed both on-treatment toxicity and on-t...

Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans

Details
Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Dr. Morgans shares her thoughts on the importance of collaboration across teams in treating patients with GU cancers and provides an overview of key content in the book. Biographies: Alicia Morgans, MD, MPH , Genitourinary...

Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang

Details
Clara Hwang shares an overview of her ASCO 2022 poster session presentation with Alicia Morgans. Dr. Hwang explains how the research was motivated by the known disparities in Black versus white men regarding prostate cancer diagnosis and prognosis. She then describes how this study explored these disparities within the prostate cancer precision medicine space. Biographies: Clara Hwang, MD, Medical...

The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff

Details
Phil Kantoff, CEO of Convergent Therapeutics, sits down with Alicia Morgans to discuss the future of radioligand therapy in the treatment of advanced prostate cancer. Philip Kantoff provides an overview of exciting results seen in studies on actinium-225, a powerful alpha-emitter tested in patients with advanced prostate cancer that also may be promising for patients with earlier-stage disease. Bi...

Cancer Survivorship and PCF - Matthew Smith & Alicia Morgans

Details
Alicia Morgans and Matthew Smith join Charles Ryan to discuss cancer survivorship. Drs Morgans and Smith explain the holistic role that a cancer survivorship program plays in the health and well-being of prostate cancer patients, including bone health, mental health, monitoring cardiovascular risk, and more. Biographies: Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, A...

Extending Prostate Genetic Awareness, Navigation and Delivery for Genetic Testing in Males of African American Decent - The EXPAND Network, 2021 PCF-Pfizer Global Health Equity Challenge Award - Veda...

Details
Veda Giri joins Charles Ryan in a discussion on the EXPAND Network, EX tending P rostate Cancer Genetic A wareness, N avigation, and D elivery for genetic testing, and genetic awareness in males of African descent for Black men. This project is supported by the 2021 PCF-Pfizer Health Equity Challenge Award grant mechanism. Dr. Giri provides the rationale for this project stemming from statistics f...

Immune Checkpoint B7-H3 - APCCC 2022 - Emmanuel Antonarakis

Details
Emmanuel Antonarakis joins Alicia Morgans to discuss the immune checkpoint B7-H3 and its implications for prostate cancer treatment. Dr. Antonarakis provides an overview of clinical trials that tested B7-H3 and the encouraging findings of those trials. He also details some of the toxicities noted during the trials and plans for future studies given the measurable disease responses and PSA response...

Timing and Intensity of ADT in Biochemical Recurrence - Channing J. Paller

Details
Channing Paller joins Alicia Morgans at ASCO 2022 to discuss considerations in the timing and intensity of ADT in biochemical recurrence. Dr. Paller gives an overview of her presentation and the two explore important considerations when timing treatment for prostate cancer after recurrence and relevant clinical trial data, such as TOAD and CRUK. In addition, they acknowledge the importance of pati...

When and How Much: A Deep Dive into the RADICALS Trial's Questions on Radiotherapy and Hormone Therapy - Nicholas James

Details
Alicia Morgans interviews Nicholas James about the RADICALS trial, a complex study aiming to determine the optimal timing for radiotherapy after surgery and the amount of hormone therapy needed. The first question's data showed that waiting was safe and adjuvant therapy unnecessary. The second question, presented at ESMO, involved pragmatic randomization between zero, six, and 24 months of ADT, re...